Cryptosporidiosis (Infectious Disease) - Drugs in Development, 2021

September 2021 | 36 pages | ID: C8C80AB7BC77EN
Global Markets Direct

Abstracts

Cryptosporidiosis (Infectious Disease) - Drugs in Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cryptosporidiosis - Drugs In Development, 2021, provides an overview of the Cryptosporidiosis (Infectious Disease) pipeline landscape.Cryptosporidiosis is an intestinal illness caused by a microscopic parasite called Cryptosporidium. Symptoms include watery diarrhea, dehydration, and lack of appetite, weight loss, fever, nausea and vomiting. Risk factors include contaminated water, animal handlers and parents of infected children.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cryptosporidiosis - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Cryptosporidiosis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Cryptosporidiosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Cryptosporidiosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Preclinical and Discovery stages are 4 and 4 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Cryptosporidiosis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Cryptosporidiosis (Infectious Disease).
• The pipeline guide reviews pipeline therapeutics for Cryptosporidiosis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Cryptosporidiosis (Infectious Disease) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Cryptosporidiosis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Cryptosporidiosis (Infectious Disease)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Cryptosporidiosis (Infectious Disease).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Cryptosporidiosis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Cryptosporidiosis - Overview
Cryptosporidiosis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Cryptosporidiosis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cryptosporidiosis - Companies Involved in Therapeutics Development
AbbVie Inc
Aviex Technologies LLC
Epichem Pty Ltd
ioGenetics Inc
Novartis AG
PGTx Ltd
Cryptosporidiosis - Drug Profiles
AV-0215W - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AV-0216W - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
clofazimine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DBAF-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EDI-408 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EPLAJ-1317 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KDU-731 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Vector Vaccine for Protozoal Infection - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CDPK1 for Protozoal Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cryptosporidiosis - Dormant Projects
Cryptosporidiosis - Discontinued Products
Cryptosporidiosis - Product Development Milestones
Featured News & Press Releases
Mar 14, 2018: Calibr's repurposed drug to treat non-viral diarrhea enters into a clinical trial
Feb 14, 2018: Novartis forms alliance to develop medicines for treating infectious diarrheal disease
May 31, 2017: Progress reported in global fight against diarrheal disease cryptosporidiosis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Cryptosporidiosis, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Cryptosporidiosis - Pipeline by AbbVie Inc, 2021
Cryptosporidiosis - Pipeline by Aviex Technologies LLC, 2021
Cryptosporidiosis - Pipeline by Epichem Pty Ltd, 2021
Cryptosporidiosis - Pipeline by ioGenetics Inc, 2021
Cryptosporidiosis - Pipeline by Novartis AG, 2021
Cryptosporidiosis - Pipeline by PGTx Ltd, 2021
Cryptosporidiosis - Dormant Projects, 2021
Cryptosporidiosis - Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Cryptosporidiosis, 2021
Number of Products under Development by Companies, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Routes of Administration, 2021
Number of Products by Top 10 Molecule Types, 2021
Number of Products by Stage and Top 10 Molecule Types, 2021